Sign In
Buy ICCM
$0.152
+0.0127 (+9.14%)
At Close: Jun 03, 2026
ProSense® is the first and only medical device to be granted FDA marketing authorization for the local treatment of breast cancer Major advancement and new paradigm in breast cancer care as a simple,
IceCure's exclusive workshop was filled to capacity – Unlocking De-Escalation of Care: Cryoablation for Breast Cancer led by Key Opinion Leaders Dr. Federica Di Naro and Dr. Lucía Graña-Lopez
Presentations from 5 Key Opinion Leaders on ProSense® cryoablation including 3 independent studies on breast cancer and 1 on endometriosis 3 hands-on training sessions for doctors interested in
IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes
08:30am, Thursday, 18'th Sep 2025
The invention is designed to improve cryoprobe extraction, further reducing risk of tissue trauma, leading to lower costs and improved patient experience XSense™ System with Cryoprobes recently rec
Approved for a broad range of indications including in gynecology, oncology and general surgery CAESAREA, Israel , Sept. 15, 2025 /PRNewswire/ -- IceCure Medical Ltd.
Article published in European Journal of Surgical Oncology focused on cosmetic outcomes and patient satisfaction reports 95% of patients were very satisfied or satisfied with thermal ablation Article
IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy
08:30am, Thursday, 04'th Sep 2025
Independent study reports pain scores declined from a median of 8 on a scale of 0-10 to a median of 0 for patients who had ProSense® cryoablation procedures ProSense® is FDA cleared and approved in
IceCure Medical Ltd (ICCM) Q2 2025 Earnings Call Transcript
01:08pm, Wednesday, 13'th Aug 2025
IceCure Medical Ltd (NASDAQ:ICCM ) Q2 2025 Earnings Conference Call August 13, 2025 10:00 AM ET Company Participants Michael Polyviou - IR, EVC Group Inc. Eyal Shamir - CEO & Director Ronen Tsimerman
IceCure Medical Ltd. (ICCM) Q2 Earnings Surpass Estimates
10:41am, Wednesday, 13'th Aug 2025
IceCure Medical Ltd. (ICCM) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.06 per share.
IceCure Reports Financial & Operational Results for the First Half of 2025
08:30am, Wednesday, 13'th Aug 2025
$10 million two-times over-subscribed rights offering creates cash runway to anticipated FDA marketing authorization decision for ProSense® in women aged 70+ with early-stage low risk breast cancer C
IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025
08:30am, Wednesday, 06'th Aug 2025
CAESAREA, Israel , Aug. 6, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destro
CAESAREA, Israel , July 29, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that dest
Breast surgeon, Professor Eisuke Fukuma, a highly regarded cryoablation expert & ProSense® user at Kameda Medical Center, presented updated breast cancer cryoablation data from an independent study
IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period
09:00am, Thursday, 24'th Jul 2025
CAESAREA, Israel , July 24, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that dest
IceCure Announces Commencement of Rights Offering
08:00am, Thursday, 10'th Jul 2025
CAESAREA, Israel , July 10, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that dest
